Table 5.
Prognostic models: international prognostic factor study group score.
| Factors | Points | |||
|---|---|---|---|---|
| Primary site | Gonadal | 0 | ||
| Retroperitoneal | 1 | |||
| Mediastinal (NSGCT) | 3 | |||
| Response to first-line therapy | CR/PR− | 0 | ||
| PR+/SD | 1 | |||
| PD | 2 | |||
| Progression-free interval after first-line therapy | >3 months | 0 | ||
| ≤3months | 1 | |||
| Serum hCG level | ≤1000 IU/l | 0 | ||
| >1000 IU/l | 1 | |||
| Serum AFP level | Normal | 0 | ||
| ≤1000 ng/ml | 1 | |||
| >1000 ng/ml | 2 | |||
| Liver, bone or brain metastases | Absent | 0 | ||
| Present | 1 | |||
| Add points for preliminary score (0–10); regroup into category score: (0): 0; (1–2): 1; (3–4): 2; (5 or more): 3 Add histology points as below to category score to determine final risk category | ||||
| Histology | Seminoma | −1 | ||
| NSGCT/mixed | 0 | |||
| Stratification | Points | 2-year PFS (%) | 3-year OS (%) | |
| Very low risk | −1 | 75 | 77 | |
| Low risk | 0 | 51 | 66 | |
| Intermediate risk | 1 | 40 | 58 | |
| High risk | 2 | 26 | 27 | |
| Very high risk | 3 | 6 | 6 | |
AFP: α-feto protein; CR: Complete response; DFS: Disease-free survival; FFS: Failure-free survival; hCG: Human chorionic gonadotropin; NSGCT: Nonseminomatous germ cell tumor; OS: Overall survival; PD: Progression of disease; PFS: Progression-free survival; PR−: Partial response with negative markers; PR+: Partial response with positive markers; SD: Stable disease.
Data taken from [48].